Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.51 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.51 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.49 |
| ▸ | PRMT5 | O14744 | 2/20 | 0.49 |
| ▸ | WDR77 | Q9BQA1 | 2/20 | 0.49 |
| ▸ | SLC5A7 | Q9GZV3 | 1/20 | 0.47 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | AURKA | O14965 | 1/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.43 |
| ▸ | GPR88 | Q9GZN0 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12437481 | 0.91 | ROCK2 (0.48) | KMT2AMEN1ROCK2ROCK1OPRK1 | |
| SCHEMBL12437594 | 0.90 | LMNA (0.51) | KMT2AMEN1ROCK2ROCK1SLC5A7 | |
| SCHEMBL12437608 | 0.87 | KMT2A (0.55) | KMT2AMEN1ROCK2ROCK1OPRK1 | |
| SCHEMBL12437387 | 0.86 | MEN1 (0.61) | KMT2AMEN1OPRK1PRMT5WDR77 | |
| SCHEMBL12437359 | 0.85 | MEN1 (0.59) | KMT2AMEN1PRMT5WDR77SLC5A7 | |
| SCHEMBL13925138 | 0.83 | KMT2A (0.53) | KMT2AMEN1OPRK1PRMT5WDR77 | |
| SCHEMBL12437578 | 0.83 | MEN1 (0.55) | KMT2AMEN1OPRK1PRMT5WDR77 | |
| SCHEMBL14435687 | 0.80 | ALDH1A1 (0.53) | KMT2AMEN1ROCK2ROCK1SLC5A7 | |
| SCHEMBL12513930 | 0.80 | GAA (0.53) | KMT2AMEN1OPRK1PRMT5WDR77 | |
| SCHEMBL12513922 | 0.79 | ATM (0.52) | KMT2AMEN1OPRK1PRMT5WDR77 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110178066-A1 | Hydroxypiperidine derivatives and uses thereof | AVALON PHARMACEUTICALS | 2011-07-21 | — | — | US | disclosed |
| US-20110178066-A1 | Hydroxypiperidine derivatives and uses thereof | AVALON PHARMACEUTICALS | 2011-07-21 | — | — | US | disclosed |
| US-20090036429-A1 | Hydroxypiperidine Derivatives and Uses Thereof | AVALON PHARMACEUTICALS | 2009-02-05 | — | — | US | disclosed |
| US-20090036429-A1 | Hydroxypiperidine Derivatives and Uses Thereof | AVALON PHARMACEUTICALS | 2009-02-05 | — | — | US | disclosed |
| WO-2007098086-A2 | HYDROXYPIPERIDINE DERIVATIVES AND USES THEREOF | AVALON PHARMACEUTICALS (US) | 2007-08-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178066-A1 | Hydroxypiperidine derivatives and uses thereof | HPGDS, HPGD, DPYD | KMT2A 2446/4885MEN1 3974/4885ROCK2 3546/4885 |
| US-20090036429-A1 | Hydroxypiperidine Derivatives and Uses Thereof | HPGDS, HPGD, DPYD | KMT2A 2446/4885MEN1 3974/4885ROCK2 3546/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.